Recent Updates — HYFT

MindWalk Holdings Corp. announced that Thomas Lynch has departed the company and ceased to serve as its Chief Business Officer, effective October 16, 2026. CEO Jennifer Bath thanked Lynch for his contributions and stated that commercial priorities remain unchanged. The company emphasized that it is focused on delivering contracted platform deployments with life sciences customers and advancing pharma engagements. Commercial and business development responsibilities now report directly to the Chief Executive Officer. MindWalk Holdings Corp. operates in the biotechnology sector, building Bio-Native AI infrastructure for drug discovery.

MindWalk Holdings Corp. announced the appointment of three senior executives to its Boston-based leadership team as its pipeline advances toward preclinical efficacy studies. Zachary Maben joins as Director, Antigen Discovery & Protein Engineering from Arbor Biotechnologies and previously Pfizer. Joanne Lim arrives as Director, Preclinical Development from Orum Therapeutics and previously Novartis. Shuji Sato expands his responsibilities to include the Company’s pipeline. MindWalk Holdings Corp. is a Bio-Native AI company building biological intelligence infrastructure for drug discovery.